Why Sarepta Therapeutics Stock Is Rising Today
Shares of mid-cap biotech Sarepta Therapeutics (NASDAQ: SRPT) marched almost 11% higher Wednesday morning on elevated volume. The stock's rally was catalyzed by news of encouraging results from an early-stage muscle biopsy study for its experimental Duchenne muscular dystrophy (DMD) therapy, known as golodirsen. Duchenne is a genetic disorder causes muscle wasting; it primarily afflicts young boys, and is the result of a mutation on the X chromosome.
Golodirsen targets patients with deletions of the DMD gene amenable to skipping exon 53. If approved, it would complement the company's first DMD commercial product, Exondys 51. As of 10:30 a.m. EDT Wednesday, Sarepta's shares were up by 10.5%.
Image Source: Getty Images.
Source: Fool.com
Sarepta Therapeutics Stock
The community is currently still undecided about Sarepta Therapeutics with 1 Buy predictions and 0 Sell predictions.
On the other hand, the target price of 130 € is below the current price of 132.3 € for Sarepta Therapeutics, so the potential is actually -1.74%.